unknown
Stage
About
Develops small-molecule therapeutics aimed at restoring mitochondrial function to treat neurodegenerative and rare diseases; the company cites over ten years of R&D and a proprietary library of 700+ novel compounds.
Explore Cristae Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.